Prevalence of schistosomiasis and its association with anemia among pregnant women: a systematic review and meta-analysis

Ishag Adam1, Nadiah A. ALhabardi1, Osama Al-Wutayd2* and Ammar H. Khamis3

Abstract

Background: Schistosomiasis is a highly prevalent parasitic disease that can lead to adverse maternal and perinatal outcomes. To our knowledge, there has been no systematic review and meta-analysis of schistosomiasis during pregnancy.

Methods: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Relevant published studies were searched in international databases (PubMed, Science Direct, Scopus, Web of Science, and Google Scholar), from their inception until May 31, 2020. The retrieved studies were assessed for quality using the Modified Newcastle-Ottawa Scale. OpenMeta Analyst software was used for the statistical analysis.

Results: Thirty-two studies enrolling 21024 pregnant women were included in this meta-analysis. All 32 of these studies were conducted in Africa. Of these studies, 19, 11, and 2 investigated S. mansoni, S. haematobium, and combined S. mansoni and S. haematobium infections, respectively. The pooled prevalence estimate of schistosomiasis during pregnancy was 13.2% (95 CI 11.0–15.4). A random model was used because of high heterogeneity (Q = 99.14; P < 0.001). In subgroup analyses, the pooled prevalence estimate of S. haematobium was significantly higher than the pooled prevalence estimates of S. mansoni [22.5% (95% CI 1.6–43.5) vs 8.7% (95% CI 6.0–11.3, P = 0.016), respectively]. The results of meta-regression analyses showed a non-significant difference in the prevalence of schistosomiasis during pregnancy according to the study sample sizes and year of publication. Only six studies evaluated the association between schistosomiasis during pregnancy and anemia. Schistosomiasis was associated with anemia in these six studies (OR = 3.02, 95% = 1.25–7.28, P = 0.014).

Conclusion: The present meta-analysis suggests that schistosomiasis during pregnancy is an existing health problem. This meta-analysis also highlights the lack of data on the determinants and outcomes of schistosomiasis during pregnancy. Preventive measures are needed and could be part of antenatal care in areas endemic with schistosomiasis.

Keywords: Prevalence, Pregnancy, Schistosoma haematobium, Schistosoma mansoni

Introduction

Schistosomiasis, also known as bilharzia, is a water-borne helminthic infection caused by parasitic flatworms belonging to Schistosoma spp. blood flukes. It is a highly prevalent parasitic disease worldwide that causes disease in over 200 million people, 90% of whom live in Africa [1]. The life cycle of schistosomes includes freshwater snails as intermediate hosts, from which infective cercariae
are released into fresh water and can penetrate unbroken human skin. Schistosomiasis is especially prevalent in countries with tropical climates and limited access to clean water [1]. It was estimated that, in 2014, 40 million women of reproductive age had schistosomiasis (Schistosoma haematobium, S. japonicum, and/or S. mansoni) [2]. During pregnancy, helminth infections, including schistosomiasis, can lead to modulation of the immune response (change from Th1 toward Th2), increasing the susceptibility of pregnant women to various infections, such as influenza, malaria, measles, and toxoplasmosis, and their severity and can further lead to immune modulation in newborns [3, 4]. Previous studies have reported that schistosomiasis in pregnancy is associated with anemia [5–7]. Moreover, schistosomiasis, especially the urogenital type, might lead to adverse outcomes, such as low birth weight deliveries, preterm deliveries, and infertility [8, 9]. Although several studies on schistosomiasis during pregnancy have been conducted in different countries [6–8, 10–38], empirical estimates of the global disease burden during pregnancy are lacking. However, the estimation of the global burden of schistosomiasis during pregnancy is of paramount importance, as it will guide preventive measures and other interventions. The current systematic review and meta-analysis was conducted to estimate the pooled prevalence of schistosomiasis and its association with anemia among pregnant women.

Methods
We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in this study [39]. The included studies were assessed by using the Joanna Briggs Institute Meta-Analysis of Statistics Assessment and Review Instrument (JBI-MAStARI) [40]. Two investigators (NAA and HZH) independently searched and identified eligible studies. If there was disagreement, it was resolved by discussion with a third researcher (IA). The extracted data (author’s name, year of publication, study site, type of study, number of pregnant women with schistosomiasis, and total number of pregnant women enrolled) were recorded in an Excel sheet (Additional file 1).

Search strategy
A comprehensive literature search was conducted in international databases (PubMed, Science Direct, Scopus, Web of Science, and Google Scholar, from their inception until May 31, 2020) to evaluate the prevalence of schistosomiasis in pregnant women. The searches were performed using MeSH terms either alone or in combination: “[schistosoma,” “schistosomiasis,” “bilharzia,” “bilharziasis” OR “Schistosoma mansoni” OR “Schistosoma haematobium” OR “Schistosoma japonicum” AND (“Prevalence” OR “Epidemiology”) AND (“Pregnancy” OR “Pregnant women”) AND (“Anemia” OR “Hemoglobin”). The references of the included articles were searched further for more suitable articles.

Articles were included in the meta-analysis if they met the following inclusion criteria: all cross-sectional studies published in peer-reviewed journals and reporting the prevalence of schistosomiasis in pregnant women, full text or abstract, in the English language, and investigating at least one type/species of schistosomiasis using standard parasitological methods. Case reports, letters, animal studies, duplicates, reviews, and articles in languages other than English were excluded (Fig. 1).

The quality of each study was assessed using the Modified Newcastle–Ottawa Scale (NOS) for cross-sectional or case-control studies [41]. Three major domains—the selection of participants, comparability of study groups, and ascertainment of outcomes of interest in each study—were evaluated by the NOS, with a maximum of nine stars. High-quality studies were assigned if the NOS score was ≥7 stars (Table 1).

Statistical analysis
We used OpenMeta Analyst software for Windows [42, 43] to perform the meta-analyses. The heterogeneity of the included studies was evaluated according to Cochrane Q and I². I² values of 25%, 50%, and 75% were considered to represent low, moderate, and high heterogeneity, respectively [44]. The random-effects model was used in case of significant heterogeneity between studies; otherwise, the fixed-effects model (Mantel-Haenszel method) was used for analysis. The pooled prevalence of schistosomiasis and the 95% confidence interval (95% CI) were recorded. Subgroup/meta-regression analysis (size of study, year of publication, and type of infection) was conducted to detect the source of heterogeneity. Moreover, the pooled OR and 95% CI were computed for the association between schistosomiasis and anemia. Funnel plots and Egger’s test were used to assess the publications. A P-value was considered statistically significant if it was < 0.05.

Result
A total of 308 records were identified and 146 duplicated articles were removed. The remaining 162 records were screened using the titles and abstracts, and 121 were excluded. Full texts of 41 articles were then evaluated according to eligibility criteria. Nine articles were also excluded. Finally, 32 articles were included in the study as they passed the eligibility criteria and quality assessment (Fig. 1).

Thirty-two studies enrolling 21,024 pregnant women were included in this meta-analysis [6–8, 10–38]. The
sample size ranged from 120 [30] to 4437 pregnant women [19]. All of these studies were of high quality (Table 1).

**Countries**

All 32 of the studies were conducted in Africa. Six, five, and four studies were conducted in Ethiopia [11, 17, 24, 29, 31, 34], Nigeria [14, 20, 25, 30, 37], and Uganda [6, 12, 16, 27], respectively. One study was conducted in Democratic Republic of Congo [15], Côte d'Ivoire [36], Sudan [10], Gabon [8], and Zimbabwe [19] (Fig. 2).

**Species**

Among these 32 studies, 19, 11, and 2 studies investigated *S. mansoni* [7, 10–12, 16, 17, 22, 24, 26–31, 33, 34, 36–38], *S. haematobium* [8, 13–15, 18–21, 25, 32, 35], and combined infections of *S. mansoni* and *S. haematobium* [6, 23], respectively.

**Prevalence**

The prevalence of schistosomiasis ranged from 0% in Ghana [33] to 63.0% in Tanzania [7]. The pooled prevalence estimate of schistosomiasis during pregnancy was 13.2% (95% CI 11.0–15.4). A random model was used because of high heterogeneity ($Q = 99.14$, $P < 0.001$; Fig. 3).

In subgroup analyses, the pooled prevalence estimate of *S. haematobium* was significantly higher than the pooled prevalence estimate of *S. mansoni* (22.5%...
The results of the meta-regression analyses showed a non-significant difference in the prevalence of schistosomiasis during pregnancy based on the study sample size (coefficient = $-0.001$, 95% CI: $-0.001$ to $0.001$, $P = 0.538$) and year of publication ($C = -0.002$; 95% CI: $-0.010$ to $0.007$, $P = 0.697$) (Table 2). Egger’s test showed probable publication bias ($P = 0.005$; Fig. 5).

**Discussion**

The main finding of the current meta-analysis was that all the retrieved studies on schistosomiasis during pregnancy were conducted in Africa. Moreover, all these studies documented *S. haematobium* and *S. mansoni* infections without any reports of *S. japonicum*. Sub-Saharan African countries account for more than two-thirds (70%) of schistosomiasis cases. *S. haematobium* and *S. mansoni* infections predominate in Africa [45]. It is worth mentioning that epidemiological data on schistosomiasis during pregnancy are generally scarce in sub-Saharan Africa, as the majority of studies are conducted on schoolchildren [46]. We did not identify any articles on the prevalence of schistosomiasis during pregnancy outside of Africa (Southeast Asia of Latin America). Perhaps there are publications on schistosomiasis during pregnancy in these settings, but they are in languages other than English. We included only published articles in English, which could explain the presence of publication bias in our findings. In Latin America and Southeast Asia, the identified reports addressed the pathophysiology rather than the epidemiology of schistosomiasis during pregnancy [4, 47]. However, in these settings in which there are no published articles on schistosomiasis during pregnancy, there are meta-analyses on schistosomiasis available for other age groups [48, 49]. Moreover, a previous study on *S. japonicum* during pregnancy assessed the

| Covariate                  | Coefficient | 95% confidence interval | Standard error | $P$  |
|----------------------------|-------------|-------------------------|----------------|------|
| Size                       | $-0.001$    | $-0.001$ to $0.001$     | $<0.001$       | 0.538|
| Year of publication        | $-0.002$    | $-0.010$ to $0.007$     | $-0.004$       | 0.697|
| Type of infection          | 0.097       | 0.018 to 0.176          | 0.04           | 0.016|
pathophysiology rather than the prevalence of schistosomiasis during pregnancy [50].

The current meta-analysis showed a pooled prevalence estimate of schistosomiasis during pregnancy of 13.2%. A previous meta-analysis showed a reported pooled prevalence estimate for S. haematobium among adults of 54% [51].

Although only six studies assessed the association between schistosomiasis and anemia, the current meta-analysis showed that pregnant women with schistosomiasis were at three times higher risk of anemia (pooled OR = 3.02). Previous studies have reported that schistosomiasis in pregnancy is associated with anemia [5–7]. In a systematic review and meta-analysis, Kassebaum et al. reported that malaria and schistosomiasis were the main conditions that increased the prevalence of anemia [53]. Although the exact pathophysiological mechanism of anemia and its associations with schistosomiasis have yet to be fully explained, hemolysis, inflammatory processes, and bone marrow suppression are plausible explanations for anemia and schistosomiasis [52]. Interestingly, few studies (six) assessed the association between schistosomiasis during pregnancy and anemia, and there was no available meta-analysis of this topic. It is possible that researchers do not feel it is important to document this association, and it might be considered an established fact rather than an area for research. A recent meta-analysis showed that mass deworming during pregnancy reduces maternal anemia by 23%; however, there is no evidence of it having an impact on any other maternal or pregnancy outcomes [54].

Other effects of schistosomiasis on pregnancy outcomes, such as reduced maternal-to-infant antibody transfer [50, 55], infertility, preterm deliveries, and lower birth weights [9], need to be addressed. The adverse effects of schistosomiasis during pregnancy could be explained by the modulation of the immune response (change from Th1 toward Th2), which could be accompanied by immune modulation in newborns [3, 4].

Researchers might have investigated schistosomiasis epidemiology and its treatment (praziquantel) among children [56]. Regarding praziquantel safety during pregnancy, it was long indicated that “no data during pregnancy” were available. Following our reports on praziquantel safety during pregnancy [57, 58], it has come to be indicated as a safe, effective drug [59].

![Fig. 2 Number of studies included from each country.](image-url)
| Studies                     | Estimate (95% C.I.) | SE/Trt |
|-----------------------------|---------------------|--------|
| Adewale et al., 2018        | 0.008 (0.000, 0.025) | 1/120  |
| Ahenkrah et al., 2016       | 0.002 (0.000, 0.007) | 1/400  |
| Ajenga et al., 2006         | 0.635 (0.605, 0.665) | 817/972|
| Alem et al., 2013           | 0.005 (0.000, 0.012) | 2/384  |
| Anchang–Kimbi et al., 2017  | 0.468 (0.406, 0.530) | 117/250|
| Ayaya et al., 2006          | 0.229 (0.157, 0.301) | 30/131 |
| Botka et al., 2019          | 0.023 (0.007, 0.039) | 8/349  |
| Coulibaly et al., 2017      | 0.027 (0.010, 0.045) | 9/331  |
| Derso et al., 2016          | 0.029 (0.012, 0.045) | 11/384 |
| Egwumuganya et al., 2001    | 0.034 (0.022, 0.047) | 28/816 |
| Eyo et al., 2012            | 0.238 (0.175, 0.302) | 41/272 |
| Fairley et al., 2013        | 0.306 (0.272, 0.340) | 213/696|
| Feikeke et al., 2018        | 0.174 (0.147, 0.200) | 136/783|
| Fuseini et al., 2009        | 0.123 (0.086, 0.161) | 37/300 |
| Gadot et al., 2020          | 0.174 (0.136, 0.213) | 64/367 |
| Gedofaw et al., 2015        | 0.006 (0.000, 0.013) | 2/363  |
| Kawai et al., 2009          | 0.014 (0.007, 0.022) | 14/971 |
| Keffyalew et al., 2014      | 0.023 (0.005, 0.042) | 6/258  |
| Khalid et al., 2012         | 0.130 (0.092, 0.169) | 38/292 |
| Kihara et al., 2015         | 0.267 (0.232, 0.442) | 59/258 |
| Mombo–Ngoma et al., 2016    | 0.092 (0.075, 0.109) | 103/1115|
| Muhangi et al., 2007        | 0.183 (0.164, 0.198) | 458/2507|
| Murenjekwa et al., 2020     | 0.027 (0.022, 0.032) | 113/4437|
| Ndyomugenyi et al., 2008    | 0.207 (0.204, 0.205) | 31/832 |
| Ouédraogo et al., 2012      | 0.002 (0.000, 0.005) | 2/989  |
| Oyeyemi et al., 2017        | 0.199 (0.151, 0.248) | 52/261 |
| Salawu et al., 2013         | 0.208 (0.163, 0.253) | 65/313 |
| Siegbai et al., 1994        | 0.045 (0.016, 0.076) | 5/200  |
| Tay et al., 2017            | 0.120 (0.087, 0.153) | 45/375 |
| Thijpen et al., 2011        | 0.025 (0.014, 0.035) | 21/448 |
| Tonga et al., 2019          | 0.333 (0.278, 0.398) | 54/282 |
| Wepnő et al., 2019          | 0.223 (0.180, 0.265) | 82/368 |

Overall (I²=99.14 %, P<0.001) 0.132 (0.116, 0.154) 2514/21024

**Fig. 3** Forest plots of ORs with 95% CIs for the meta-analysis of the pooled prevalence of schistosomiasis using a fixed model.
**Fig. 4** Forest plots of ORs with 95% CIs for the subgroup analysis of the type of infection in a fixed model in the meta-analysis.
Limitations of the study
Many potential risk factors, such as age and parity, were not assessed in these studies. Furthermore, the cross-sectional nature of the included studies is not amenable to the dissection of the causal relationships between schistosomiasis and anemia.

Conclusion
The present meta-analysis suggests that schistosomiasis during pregnancy is an existing health problem. This meta-analysis also highlights the lack of data on the determinants and outcomes of schistosomiasis during pregnancy. Preventive measures are needed and could be part of antenatal care in areas endemic for schistosomiasis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13071-021-04642-4.

Additional file 1. Characteristics of all studies included in this systematic review and meta-analysis of the prevalence of schistosomiasis during pregnancy.

Abbreviations
AOR: Adjusted odds ratio; CI: Confidence interval; GDM:SD: Deviation.

Acknowledgements
The authors would like to thank all the authors who published the manuscripts included in this work.
References

1. World Health Organization. Schistosomiasis. WHO Fact Sheet. 2018. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis. Accessed Dec 20.

2. Colley DG, Bustinbily AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;2:253–64.

3. Lacocca M, Prazeres da Costa CU. Maternal schistosomiasis: immunomodulatory effects with lasting impact on allergy and vaccine responses. Front Immunol. 2018;9:2623.

4. da Paz VRF, Sequeira D, Pyrrho A. Infection by Schistosoma mansoni during pregnancy: effects on offspring immunity. Life Sci. 2017;1:46–52.

5. Ag Ayoy A, Speikermann-Brouwer GM, Traoré AK, Stoltzfus RJ, Garza C. Determinants of anemia among pregnant women in Mali. Food Nutr Bull. 2006;27:13–11.

6. Tay SCK, Nani EA, Walana W. Parasitic infections and maternal anaemia among expectant mothers in the Dangme East District of Ghana. BMC Res Notes. 2017;10:1–9.

7. Ajanga A, Lvambmo NJS, Blair L, Nyandindi U, Fennick A, Brooker S. Schistosoma mansoni in pregnancy and associations with anaemia in northwest Tanzania. Trans R Soc Trop Med Hyg. 2006;100:59–63.

8. Momb kró-Ngoma G, Honkpehedji J, Basra A, Mackanga JR, Zoleko N, Zinouj I, et al. Urogenital schistosomiasis during pregnancy is associated with low birth weight delivery: analysis of a prospective cohort of pregnant women and their offspring in Gabon. Int J Parasitol. 2017;47:69–74.

9. Friedman JF, Mital P, Kanzaria HK, Olds GR, Kurtis JD. Schistosomiasis and malaria infection in coastal Kenya. Am J Trop Med Hyg. 2013;88:48–53.

10. Eyo JE, Onyishii GC, Okafor FC. Urinary schistosomiasis among pregnant women in some endemic tropical semi-urban communities of Anambra State. Nigeria Trop Biomed. 2012;29:75–9.

11. Gathod A, Mvumbi G, Hoff NA, Musene K, Mukadi P, Ashbaugh HR, et al. Urogenital schistosomiasis and sexually transmitted coinfections among pregnant women in a schistosome-endemic region of the Democratic Republic of Congo. Am J Trop Med Hyg. 2019;101:826–36.

12. Muchangi L, Woodburn P, Omara M, Omoding N, Kizito D, Mpairwe H, et al. Associations between mild-to-moderate anaemia in pregnancy and helminth, malaria and HIV infection in Entebbe, Uganda. Trans R Soc Trop Med Hyg. 2007;101:899–907.

13. Kefyalew F, Zemen E, Asres Y, Gedefaw L. Anemia among pregnant women in Southeast Ethiopia: prevalence, severity and associated risk factors. BMC Res Notes. 2014;7.

14. Khara JH, Kutima HL, Ouma J, Churer CH, Changoma JM, Mwalisesto MA, et al. Urogenital schistosomiasis in women of reproductive age and pregnant mothers in Kwale County. Kenya J Helminthol. 2015;89:105–11.

15. Murenjekwa W, Makasi R, Ntuzi N, Chikwa E, Bunas J, Moulton LH, et al. Determinants of urogenital schistosomiasis among pregnant women and its association with pregnancy outcomes, neonatal deaths, and child growth. J Infect Dis. 2019;113.

16. Oyeyemi OT, Odaibo AB. Maternal urogenital schistosomiasis: monitoring disease morbidity by simple repeat strips. PLoS ONE. 2017;12:e0187433.

17. Siegrist D, Siegrist-Obimpeh P. Schistosoma haematobium infection in pregnancy. Acta Trop. 1992;50:317–21.

18. Ouedraogo S, Koura GK, Accrombessi MM, Bodeau-Livinec F, Mas-sougboody A, Cot M. Maternal anemia at first antenatal visit: prevalence and risk factors in a malaria-endemic area in Benin. Am J Trop Med Hyg. 2012;87:418–24.

19. Tonga Z, Bayoi CN, Tchanga FC, Yengue JF, Wepnje GB, Nkayeede BN, Kangam L, et al. Schistosomiasis among pregnant women in Njombe-Penja health district. Cameroon J Infect Dis. 2019;13:1150–8.

20. Feleke BE, Jember TH. Prevalence of helminthic infections and determinant factors among pregnant women in Mecha district, Northwest Ethiopia: a cross sectional study. BMC Infect Dis. 2018;18:1–6.

21. Salawu OT, Odaibo AB. Schistosomiasis among pregnant women in rural communities in Nigeria. J Trop Gynaecol Obstet. 2013;12:1–4. https://doi.org/10.1161/jgj.2013.01.024.

22. Thigpen MC, Filler SJ, Kazembe PN, Parise ME, Macheso A, Campbell CH, et al. Associations between peripheral Plasmodium falciparum malaria parasitemia, human immunodeficiency virus, and concurrent helminthic infection among pregnant women in Malawi. Am J Trop Med Hyg. 2011;84:79–85.

23. Ndumyugenyi R, Kabaterine N, Olsen A, Magnusson P. Malaria and hookworm infections in relation to haemoglobin and serum ferritin levels in pregnant women in Masindi district, western Uganda. Trans R Soc Trop Med Hyg. 2008;102:130–6.

24. Wepnje GB, Ananch-Kimbii JK, Ndassi VD, Lehman LG, Kimbi HK. Schisto soma haematobium infection status and its associated risk factors among pregnant women in Munyenge, South West Region, Cameroon following scale-up of communal piped water sources from 2014 to 2017: a cross-sectional study. BMC Public Health. 2014;20:191.

25. Derso A, Nibet E, Munshae A. Prevalence of intestinal parasitic infections and associated risk factors among pregnant women attending antenatal care center at Felege Hiwot Referral Hospital, northwest Ethiopia. BMC Infect Dis. 2016;16:530.

26. Adewale B, Rahaman O, Aina O, Sulyman MA. Schistosoma mansoni and Soil Transmitted Helminth (S TH) Infections among Pregnant Women Attending Primary Health Care Facilities in Lagos Mainland. Nigeria J Biosci. Med. 2018;06:64–70.

27. Boika A, Gebremedhin S. Prevalence of intestinal parasitic infection and its association with anemia among pregnant women in Wondo Genet district, Southern Ethiopia: a cross-sectional study. J Ethop Infect Dis. 2018;29:46–52.

28. Ayoy A, Speikermann-Brouwer GM, Traoré AK, Stoltzfus RJ, Garza C. Determinants of anemia among pregnant women in Mali. Food Nutr Bull. 2006;27:3–11.

29. Ahenkorah B, Nsiah K, Baffoe P, Anto EO. Biochemical and hematological changes among anemic and non-anemic pregnant women attending
antenatal clinic at the Bolgatanga regional hospital, Ghana. BMC Hema-tol. 2018;18.
34. Alem M, Enawgaw B, Gelaw A, Kenaw T, Seid M, Olkeba Y. Prevalence of anemia and associated risk factors among pregnant women attending antenatal care in Azezo Health Center Gondar Town. Northwest Ethiopia J Interdiscip Histopathol. 2013;1:137.
35. Anchang-Kimbi JK, Elad DM, Sotoing GT, Achidi EA. Coinfection with schistosoma haematobium and Plasmodium falciparum and anaemia severity among pregnant women in Munyenge, Mount Cameroon area: a cross-sectional study. J Parasitol Res. 2017;2017.
36. Coulibaly G, Yao KP, Koffi M, Ahouty BA, Louhourignon LK, N’Cho M, et al. Paludisme et parasitoses digestives chez la femme enceinte de la commune d’Abidjan (Abidjan, Côte d’Ivoire). Bull la Société Pathol Exot. 2017;110:85–91.
37. Egwunyenga AO, Ajayi JA, Nmorsi OPG, Duhlinska‑Popova DD. Plas-modium/intestinal helminth co‑infections among pregnant Nigerian women. Mem Inst Oswaldo Cruz. 2001;96:1055–9.
38. Kawai K, Saathoff E, Antelman G, Msamanga G, Fawzi WW. Geophagy (soil‑eating) in relation to anemia and helminth infection among HIV‑infected pregnant women in Tanzania. Am J Trop Med Hyg. 2009;80:36–43.
39. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta‑analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
40. Munn Z, Moola S, Lisy K, Rittano D. The systematic review of preva‑lence and incidence data. Joanna Briggs Inst Rev Man 2014 Ed/Suppl. 2014;1–37. http://joanabriggs.org/assets/docs/sumar/ReviewersManual_2014-The Systematic-Review-of-Prevalence-and-Incidence-Data_v2.pdf. Accessed 15 Apr 2018.
41. Wells G, Shea B, O’Connell J, Peterson V, Welch V et al. Newcastle Ottawa scale assess quality nonrandomised stud meta‑analysis. http://www.ohri.ca/programs/clinical_epidemiology/oxfordasp. Accessed 21 June 2016.
42. Meta‑Analyst O. Open Meta‑Analyst – The tool | Evidence synthesis in health. https://www.brown.edu/academics/public‑health/research/evidence‑synthesis‑in‑health/open‑meta‑analyst‑tool. Accessed 17 Apr 2018.
43. Edwards A, Megens A, Peek M, Wallace EM. Sexual origins of placental dysfunction. Lancet. 2000;355:203–4.
44. Sedgwick P Meta‑analyses; heterogeneity and subgroup analysis. BMJ. 2013;989.
45. Barsoum RS, Esmat G, El‑Baz T. Human schistosomiasis: clinical perspec‑tive: review. J Adv Res. 2013;2:433–44.
46. Salawu OT, Odalbo AB. Maternal schistosomiasis: a growing concern in sub-Saharan Africa. Pathog Glob Health. 2014;108:263–70.
47. Abiyeo AI, McDonald EA, Park S, Joshi A, Kurtis JD, Wu H, et al. Maternal, placent al and cord blood cytokines and the risk of adverse birth outcomes among pregnant women infected with Schistosoma japonsicum in the Philippines. PLoS Negl Trop Dis. 2019;13:e0007371. https://doi.org/10.1371/journal.pntd.0007371.
48. Deng Y, Qiu C, Ding H, Lu D‑B. The ratio of the seroprevalence to the egg‑positive prevalence of Schistosoma japonicum in China: a meta‑analysis. BMC Infect Dis. 2018;18:404.
49. Gomes Casavechia MT, De Melo GDAN, Da Silva Fernandes ACB, De Castro KR, Pedrosso RB, Da Silva ST, et al. Systematic review and meta‑analysis on schistosoma mansoni infection prevalence, and associated risk factors in Brazil. Parasitology. 2018;298:1000–14.
50. Kurtis JD, Higashi A, Wu HW, Gundogan F, McDonald EA, Sharma S, et al. Maternal schistosomiasis japonica is associated with maternal, placental, and fetal inflammation. Infect Immun. 2011;79:1254–61.
51. Kalinda C, Mutengo M, Chimba M. A meta‑analysis of changes in schis‑tosomiasis prevalence in Zambia: implications on the 2020 elimination target. Parasitol Res. 2020;123.
52. Gasim GI, Adam I. Malaria, schistosomiasis, and related anemia. Nutr Defic. 2016;8:99.
53. Kassebaum NJ, Jasrasaria R, Naghavi M, Wulf SK, Johns N, Lozano R, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2019;2014;615–24.
54. Salam RA, Cousens S, Welch V, Gaffey M, Middleton P, Makrides M, et al. Mass deworming for soil‑transmitted helminths and schistosomiasis among pregnant women: a systematic review and individual participant data meta‑analysis. Campbell Syst Rev. 2019. https://doi.org/10.1002/ cef2.1052.
55. McKittrick ND, Vu DM, Malhotra I, King CH, Mutuku F, LaBeaud AD. Para‑sitic infections in pregnancy decrease placental transfer of antipneumococcus antibodies. Clin Vaccine Immunol. 2017;24:9.
56. Ahmed AM, El Tash LA, Mohamed EY, Adam I. High levels of Schistosoma mansoni infections among schoolchildren in central Sudan one year after treatment with praziquantel. J Helminthol. 2012;86:228–32.
57. Adam I, Elwasila ET, Homeida M. Is praziquantel therapy safe during pregnancy? Trans R Soc Trop Med Hyg. 2004;98:540–3.
58. Adam I, Elwasila E, Homeida M. Praziquantel for the treatment of schistosomiasis mansoni during pregnancy. Ann Trop Med Parasitol. 2005;99:37–40.
59. Friedman JF, Olveda RM, Mirochnick MH, Bustinduy AL, Elliott AM. Praziquantel for the treatment of schistosomiasis during human pregnancy. Bull World Health Organ. 2018;96:59–65.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.